2348.HK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 10:07):

Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally...

Stats
Šios dienos apimtis	116 000
Vidutinė apimtis	286 540
Rinkos kapitalizacija	1.79B
EPS	HKD0 ( 2023-08-25 )
Kita pelno data	( HKD0 ) 2024-05-24
Last Dividend	HKD0.0150 ( 2023-09-19 )
Next Dividend	HKD0 ( N/A )
P/E	5.17
ATR14	HKD0 (0.00%)

Dawnrays Pharmaceutical Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Dawnrays Pharmaceutical Finansinės ataskaitos

Annual	2023
Pajamos:	HKD1.15B
Bruto pelnas:	HKD641.52M (55.73 %)
EPS:	HKD0.220

FY	2023
Pajamos:	HKD1.15B
Bruto pelnas:	HKD641.52M (55.73 %)
EPS:	HKD0.220

FY	2022
Pajamos:	HKD1.28B
Bruto pelnas:	HKD766.68M (60.01 %)
EPS:	HKD0.240

FY	2021
Pajamos:	HKD1.17B
Bruto pelnas:	HKD681.26M (58.47 %)
EPS:	HKD0.230

Financial Reports:

No articles found.

Dawnrays Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.0150 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.0730 (N/A)	HKD0.0150 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Dawnrays Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.88 - good (98.76%) | Divividend Growth Potential Score: 6.07 - Stable (21.38%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.00750	2003-10-17
Last Dividend	HKD0.0150	2023-09-19
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	40	--
Total Paid Out	HKD0.998	--
Avg. Dividend % Per Year	0.00%	--
Score	3.29	--
Div. Sustainability Score	9.88
Div.Growth Potential Score	6.07
Div. Directional Score	7.97	--

Next Divdend (Est)
(2024-07-03)

HKD0.0131 Estimate 12.35 %

Dividend Stability

0.49 Below Average

Dividend Score

3.29

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2382.HK	Ex Dividend Junior	2023-05-30	Annually	0.00%
1373.HK	Ex Dividend Knight	2023-10-04	Semi-Annually	0.00%
0435.HK	Ex Dividend Knight	2023-09-21	Semi-Annually	0.00%
6812.HK	Ex Dividend Junior	2023-08-04	Sporadic	0.00%
1919.HK	Ex Dividend Knight	2023-05-30	Sporadic	0.00%
0952.HK	Ex Dividend Junior	2023-09-14	Sporadic	0.00%
0083.HK	Ex Dividend Knight	2023-10-27	Semi-Annually	0.00%
3302.HK	Ex Dividend Junior	2023-05-30	Annually	0.00%
1516.HK	Ex Dividend Junior	2023-09-27	Annually	0.00%
0564.HK	Ex Dividend Knight	2023-06-07	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.283	1.500	4.34	6.50	[0 - 0.5]
returnOnAssetsTTM	0.0900	1.200	7.00	8.40	[0 - 0.3]
returnOnEquityTTM	0.115	1.500	9.83	10.00	[0.1 - 1]
payoutRatioTTM	0.359	-1.000	6.41	-6.41	[0 - 1]
currentRatioTTM	2.57	0.800	2.14	1.714	[1 - 3]
quickRatioTTM	2.08	0.800	2.49	1.995	[0.8 - 2.5]
cashRatioTTM	1.354	1.500	3.59	5.38	[0.2 - 2]
debtRatioTTM	0.0333	-1.500	9.45	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.226	2.00	9.92	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.0926	2.00	9.95	10.00	[0 - 20]
debtEquityRatioTTM	0.0422	-1.500	9.83	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.546	1.000	4.23	4.23	[0.2 - 0.8]
operatingProfitMarginTTM	0.240	1.000	7.20	7.20	[0.1 - 0.6]
cashFlowToDebtRatioTTM	2.81	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.318	0.800	-1.215	-0.972	[0.5 - 2]
Total Score				9.88

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	5.11	1.000	9.58	0	[1 - 100]
returnOnEquityTTM	0.115	2.50	9.89	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.0926	2.00	9.97	10.00	[0 - 30]
dividendYielPercentageTTM	7.93	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.226	2.00	9.92	10.00	[0 - 30]
payoutRatioTTM	0.359	1.500	6.41	-6.41	[0 - 1]
pegRatioTTM	0.134	1.500	-2.44	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.294	1.000	5.15	0	[0.1 - 0.5]
Total Score				6.07

Dawnrays Pharmaceutical

Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. The company offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, and oral antibiotics. It also provides and system specific medicines comprising cardiovascular systems; anti-allergic, anti-HBV, and digestive systems; urinary systems; and anti-pyretic analgesic, respiratory, and endocrine system drugs in the form of tablets, capsules, and granules. The company was founded in 1995 and is headquartered in Wan Chai, Hong Kong. Dawnrays Pharmaceutical (Holdings) Limited is a subsidiary of Fortune United Group Limited.